Skip to main content
. Author manuscript; available in PMC: 2024 May 28.
Published before final editing as: ACS Nano. 2022 Nov 28:10.1021/acsnano.2c08360. doi: 10.1021/acsnano.2c08360

Figure 5.

Figure 5.

In vivo protection against P. aeruginosa pneumonia. In a-f, mice were vaccinated on days 0 and 7 with free OMVs or OM-NDs, challenged intratracheally with P. aeruginosa on day 14, and euthanized after another 24 h for analysis. (a) Bacterial load in the lungs (n = 4, mean + SD). (b) Anti-outer membrane (anti-OM) IgG titers in the bronchoalveolar lavage fluid (n = 4, mean + SD). (c-f) Concentration of IL-6 (c), IL-12p40 (d), IL-17a (e), and TNFα (f) in the bronchoalveolar lavage fluid (n = 4, mean + SD). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 (compared to OM-ND); one-way ANOVA.